Prime Studies Show High Costs Among Asthma, HAE Biologics
Prime Therapeutics LLC recently released the results of two studies focused on two classes of high-cost biologics, asthma and hereditary angioedema (HAE). Both conditions have seen new therapies recently and may be ...
SDMC Pharmacist, Integrated Data Can Produce Savings
High cost is only one characteristic of specialty drugs that makes managing them so important. They fall under both the pharmacy and medical benefits, they have complicated treatment regimens, and they have fraud, w...
New FDA Specialty Approvals
✦ April 8: The FDA granted an additional approval to Pfizer Inc. subsidiary Array BioPharma Inc.’s Braftovi (encorafenib) in combination with Lilly USA, LLC’s Erbitux (cetuximab) for the treatment of adults wi...
News Briefs
✦ Ontruzant (trastuzumab-dttb) launched on April 15. Merck & Co., Inc. will commercialize the Herceptin (trastuzumab) biosimilar in the U.S. per a deal with Samsung Bioepis Co., Ltd. Ontruzant is available in ...
Specialty Pharmacies Have Many Roles to Play During Outbreak
As the COVID-19 pandemic continues its assault on the globe and the U.S. passes 12,000 deaths from it, all eyes are on the health care industry. While the public looks to pharma manufacturers for potential treatment...
Manufacturers Can Assist Other Stakeholders in COVID Battle
As the new coronavirus continues its spread, pharma companies are finding themselves facing a spate of challenges. And although they’ll need to find ways to counter those setbacks, they also can help address issue...
Sarclisa Is Likely to Be Managed At Parity With Similar Drugs
On March 2, the FDA approved Sanofi’s Sarclisa (isatuximab-irfc) for the treatment of multiple myeloma, a hematologic malignancy. The move added another therapy to a class full of products, both indicated for the ...
CVS Enters Deal to Purchase, Rebrand Schnucks Pharmacies
CVS Pharmacy is expanding its co-branding efforts through a recently unveiled deal with Schnuck Markets Inc. by which it will acquire the company’s retail and specialty pharmacy businesses. CVS, a subsidiary of...
New FDA Specialty Approvals
✦ March 9: The FDA approved Acacia Pharma Group plc’s Barhemsys (amisulpride) for the prevention of postoperative nausea and vomiting in adults either alone or with an antiemetic of a different class and treatme...
News Briefs
✦ Herzuma (trastuzumab-pkrb) launched on March 16, bringing the total number of Herceptin (trastuzumab) biosimilars to four. Herzuma, from Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical In...